Results 11 to 20 of about 142,846 (219)

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection

Frontiers in Immunology, 2023
Chimeric antigen receptor (CAR)-T cell therapy is an innovative treatment for CD19-expressing lymphomas. CAR-T cells are primarily manufactured via lentivirus transfection or transposon electroporation.
Anna Niu, Jintao Zou, Xuan Hu, Zhang Zhang, Lingyu Su, Lingyu Su, Jing Wang, Xing Lu, Xing Lu, Wei Zhang, Wei Chen, Xiaopeng Zhang   +11 more
doaj   +1 more source

Engineering CAR-T cells

Biomarker Research, 2017
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors.
Cheng Zhang, Jun Liu, Jiang F. Zhong, Xi Zhang   +3 more
doaj   +1 more source

IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors

Frontiers in Oncology, 2021
Chimeric antigen receptor T (CAR-T) cells are not effective in solid tumor treatment due to reduced invasion and expansion, and short survival time. This study aimed to explore whether interleukin (IL)-7 and CCR2b expression could improve GD2-CAR-T cell ...
Guangchao Li, Guangchao Li, Qing Zhang, Zeping Han, Yangmin Zhu, Huijuan Shen, Zhi Liu, Zhao Zhou, Wen Ding, Siqi Han, Jinhua He, Zhao Yin, Jie Zhou, Ruiming Ou, Min Luo, Min Luo, Shuang Liu   +16 more
doaj   +1 more source

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Nature Communications, 2023
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all.
Xiaomeng Hu, Karl Manner, Rowena DeJesus, Kathy White, Corie Gattis, Priscilla Ngo, Christopher Bandoro, Eleonore Tham, Elaine Y. Chu, Chi Young, Frank Wells, Ronald Basco, Annabelle Friera, Divy Kangeyan, Pascal Beauchesne, William E. Dowdle, Tobias Deuse, Terry J. Fry, Aaron E. Foster, Sonja Schrepfer   +19 more
doaj   +1 more source

T-ALL Cells as Tool Cells for CAR T Therapy

Vaccines, 2023
T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic malignancy derived from T cells. Numerous CAR T therapies have been successfully applied to treat hematologic malignancies in the clinic.
Anqi Ren, Yuan Zhao, Haichuan Zhu
doaj   +1 more source

Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo

Frontiers in Bioscience-Landmark, 2020
Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated clinical success in treatment of B-cell hematologic cancers. In this study, we compared human Transferrin epitope tagged CAR-T cells with non-tagged CAR-T cells for cytotoxicity, IFN ...
Michael Valentine, Le Li, Hua Zhou, Shirley Xu, Jinying Sun, Chengjing Liu, Hizkia Harto, Robert Berahovich, Vita Golubovskaya, Lijun Wu   +9 more
doaj   +1 more source

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities

Frontiers in Immunology, 2023
Chimeric antigen receptor (CAR) modified T cells can induce complete remissions in patients with advanced hematological malignancies. Nevertheless, the efficacy is mostly transient and remains so far poor in the treatment of solid tumors.
Dennis Christoph Harrer, Dennis Christoph Harrer, Valerie Bezler, Jordan Hartley, Wolfgang Herr, Hinrich Abken   +5 more
doaj   +1 more source

Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology

Frontiers in Immunology, 2021
Chimeric antigen receptor (CAR)-T cell therapy has become an important method for the treatment of hematological tumors. Lentiviruses are commonly used gene transfer vectors for preparing CAR-T cells, and the conditions for preparing CAR-T cells vary ...
Xin Jin, Wenyi Lu, Meng Zhang, Xia Xiong, Rui Sun, Yunxiong Wei, Xiaoyuan He, Mingfeng Zhao, Mingfeng Zhao, Mingfeng Zhao   +9 more
doaj   +1 more source

Protocol for engineering binding domains to recognize ligand-bound receptors by using yeast surface display

STAR Protocols
Summary: Yeast surface display is a versatile protein engineering technology, enabling precise control of the applied selection pressure. We present a yeast-surface-display-based protocol for the enrichment of binders specifically recognizing ligand ...
Markus Dobersberger, Delia Sumesgutner, Charlotte U. Zajc, Michael W. Traxlmayr   +3 more
doaj   +1 more source

Clinical trials of CAR-T cells in China

Journal of Hematology & Oncology, 2017
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy.
Bingshan Liu, Yongping Song, Delong Liu
doaj   +1 more source